During the last decade, it has become evident that interactions between tumour and bone cells may change the phenotype of both populations.
Shortly after plating, 91 ± 8% of the neurons cultivated in a plain medium expressed OXA-immunoreactivity, which does normally not occur in vivo indicating that neurons may change their phenotype under non-natural culture conditions to develop synaptically coupled networks.
Published data indicate that, under a given environment, Tregs may change their phenotypes to be Foxp3+ IFN-γ+ cells, 25 or Foxp3+ IL-4+ cells, 21 or Foxp3+ IL-17+ cells.
These two examples demonstrate how important is to consider that ExMVs released during cell purification may change cell surface phenotype.
Thus, the thermal-acclimation response may change the tissue phenotype temporally to alter sensitivity to TH in a way that may parallel how different tissue types respond to TH.
In addition, persistent activation of the immune system, for example, through the continued administration of immunotherapy, may change the tumour phenotype, potentially reducing the effectiveness of treatment over time (Reiman et al, 2007).
In any case, the current data suggest that although metastatic disease may change its angiogenic phenotype compared with the primary, highly angiogenic primary tumours seem to exhibit highly angiogenic metastasis, so that assessment of the angiogenic status in primary tissues sustains a strong predictive relevance for vatalanib activity.
The data obtained herein evidence that mEHT may change TME immune phenotypes, including infiltrated leukocytes and eosinophils, and be feasibly combined with intra-tumoral DCs immunotherapy.
The phenotype may change constantly throughout the life of an individual because of environmental changes and the physiological and morphological changes associated with aging.
